FDA Approves New Catheter for Intrathecal Baclofen | medReha
3750
post-template-default,single,single-post,postid-3750,single-format-standard,bridge-core-3.0.2,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-28.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.9.0,vc_responsive

FDA Approves New Catheter for Intrathecal Baclofen

Αρχική > Ιατρικά Άρθρα  > Παθήσεις  > Νευρολογικές  > FDA Approves New Catheter for Intrathecal Baclofen

16 Σεπ FDA Approves New Catheter for Intrathecal Baclofen

Posted at 21:23h in Νευρολογικές by
0 Likes

FDA Approves New Catheter for Intrathecal Baclofen

September 14, 2012 — The US Food and Drug Administration (FDA) has approved a new catheter (Ascenda, Medtronic Inc) for use in the delivery of intrathecal baclofen (ITB) therapy.

According to the manufacturer, ITB therapy has been found in clinical trials to reduce the incidence of severe spasticity. The device is used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.

During ITB therapy, an implantable, programmable pump (SynchroMed II, Medtronic) delivers a continuous baclofen injection (Lioresal Intrathecal, Medtronic) by way of the newly approved Ascenda catheter……

Read the whole story here:

http://www.medscape.com/viewarticle/770947?src=nl_topic

 

Share
Tags:
, ,